| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS
on April 18, 2019 at 6:57 pm
Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. […]
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS
on April 16, 2019 at 8:00 pm
NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (''Fresenius'' or the ''Company'') (FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. […]
-
Fresenius Medical Care to pay $231M to resolve bribery charges
on April 2, 2019 at 5:19 pm
Fresenius Medical Care, a dialysis clinic operator, agreed Friday to pay $231 million in penalties to resolve allegations it paid bribes to win business deals in several countries, including Angola and Saudi Arabia. […]
-
Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?
on March 30, 2019 at 4:56 pm
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
-
Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges
on March 29, 2019 at 5:23 pm
Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges. […]
NYSE: FMS
